Want to see SE:SDOS full AI Analyst Report?
Top Page
ScandiDos AB
(SDOS)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.58
▼(-30.72% Downside)
Action:Reiterated
Date:09/19/26
The score is held down primarily by weak financial performance (declining revenue, ongoing net losses, and negative operating/free cash flow) and bearish technicals (price below all key moving averages with negative MACD). Low leverage and improved gross margin provide some support, but valuation remains difficult to assess given negative earnings and no dividend information.
Positive Factors
Conservative Balance Sheet
Debt of about 2.3m against 47.2m of equity indicates conservative financing and a meaningful capital cushion. This reduces near-term solvency pressure and preserves flexibility to fund product development, customer support, or working-capital needs while the business works toward profitability.
Negative Factors
Declining Revenue
TTM revenue declined 8%, indicating that demand or conversion of the company's radiotherapy QA offering has not yet produced dependable top-line expansion. Persistent contraction can reduce operating leverage, constrain investment capacity, and make fixed costs harder to absorb over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Debt of about 2.3m against 47.2m of equity indicates conservative financing and a meaningful capital cushion. This reduces near-term solvency pressure and preserves flexibility to fund product development, customer support, or working-capital needs while the business works toward profitability.
Read all positive factors
ScandiDos AB (SDOS) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr45.97M
Dividend YieldN/A
Average Volume (3M)40.55K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth-19.44%
EPS Growth-475.48%
CountrySE
Employees25
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.12
Shares Outstanding71,263,855
10 Day Avg. Volume78,843
30 Day Avg. Volume40,553
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.34
Price to Sales (P/S)1.03
P/FCF Ratio-8.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ScandiDos AB Business Overview & Revenue Model
Company Description
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and inter...
How the Company Makes Money
ScandiDos makes money primarily by selling radiation therapy QA products and related software to hospitals and radiotherapy clinics. Key revenue streams typically include: (1) hardware/system sales of measurement and verification equipment used in...
ScandiDos AB Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
63
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2023 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.97M | 54.22M | 60.43M | 60.43M | 61.55M | 57.68M |
| Gross Profit | 28.15M | -2.71M | 47.55M | 47.55M | 52.95M | 47.92M |
| EBITDA | -5.05M | -439.00K | -5.79M | -13.36M | -8.26M | -7.11M |
| Net Income | -8.21M | -3.44M | -14.65M | -14.65M | -9.12M | -7.34M |
Balance Sheet | ||||||
| Total Assets | 72.08M | 65.97M | 73.38M | 81.47M | 72.42M | 66.19M |
| Cash, Cash Equivalents and Short-Term Investments | 16.00M | 4.36M | 10.06M | 1.53M | 3.55M | 6.24M |
| Total Debt | 2.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 24.92M | 24.31M | 28.40M | 37.19M | 30.77M | 28.99M |
| Stockholders Equity | 47.16M | 41.66M | 44.98M | 44.29M | 41.65M | 37.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.50M | -6.79M | -2.71M | -1.46M | -16.31M | -2.31M |
| Operating Cash Flow | -2.79M | -2.92M | 230.00K | 1.49M | -11.90M | 2.39M |
| Investing Cash Flow | -3.84M | -3.87M | -2.94M | -2.94M | -4.37M | -4.77M |
| Financing Cash Flow | 11.66M | 0.00 | 0.00 | 0.00 | 12.33M | -83.00K |
ScandiDos AB Technical Analysis
Negative
0.83
Price Trends
0.82
Negative
0.86
Negative
0.94
Negative
Market Momentum
-0.06
Positive
26.08
Positive
6.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SDOS, the sentiment is Negative. The current price of 0.83 is above the 20-day moving average (MA) of 0.77, above the 50-day MA of 0.82, and below the 200-day MA of 0.94, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 26.08 is Positive, neither overbought nor oversold. The STOCH value of 6.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SDOS.
ScandiDos AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr56.74B | 89.36 | 30.26% | 0.38% | 13.94% | 5.70% | |
60 Neutral | kr1.53B | -302.47 | -1.22% | ― | 34.05% | -144.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | kr45.97M | -5.31 | ― | ― | -19.44% | -475.48% | |
42 Neutral | kr388.85M | -7.85 | ― | ― | -2.61% | -0.28% | |
41 Neutral | kr218.63M | -1.00 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr26.39M | -0.15 | -57.15% | ― | ― | 16.02% |
* General Sector Average
SE:SDOS
ScandiDos AB
0.65
-0.49
-42.98%
SE:PAX
Paxman AB
66.00
-3.40
-4.90%
SE:SCIB
SciBase Holding AB
15.90
-15.00
-48.55%
SE:SPEC
SpectraCure AB
0.02
-0.15
-89.16%
SE:SECT.B
Sectra AB Class B
292.20
-9.99
-3.31%
SE:OSSD
OssDsign AB
3.55
-10.37
-74.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.